Kliniska studier vid Tema Cancer

CAPItello-292. A Phase Ib/III Randomised Study of Capivasertib plusPalbociclib and Fulvestrant versus Placebo plus Palbociclib andFulvestrant in Hormone Receptor-Positive and HumanEpidermal Growth Factor Receptor 2-Negative LocallyAdvanced, Unresectable or Metastatic Breast Cancer

Theodoros Foukakis

Neo-ACT. Physical exercise during neoadjuvant chemotherapy for breast cancer as a means to increase pathological complete response rates: the randomized Neo-ACT trial

Kristina Weibring

ARIADNE. A Randomized Trial on Biology-Driven De-escalation of Neoadjuvant Treatment for HER2-positive Breast Cancer

Alexios Matikas

Taormina. Treatment of Oligometastatic breast cancer – a randomised phase 3 trial comparing stereotactic ablative radiotherapy and systemic treatment with systemic treatment alone as 1st line treatment

Kristina Weibring

LION Trial and LION-COM. Demonstrating the (cost-)effectiveness of a personalized live-remote exercise intervention for cancer survivors using a super umbrella randomized clinical trial: The LION RCT

Yvonne Wengström

MK2870-010 TroFuse-010. An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Alexios Matikas

TREAT ctDNA . Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)

Theodoros Foukakis

Destiny Breast Respond HER2-low Europe. A prospective, non-interventional study (NIS) with trastuzumab deruxtecan for patients with HER2-low expressing unresectable and/or metastatic breast cancer accompanied by a disease registry of patients treated with conventional chemotherapy

Andri Papakonstantinou

HER2-Ex PET. A multicentre, prospective, open-label study to with [68Ga]Ga-ABY-025 PET-imaging to characterize HER2-expression and explore the therapy-predictive value for HER2-antibody drug conjugates in patients with metastatic breast cancer.

Oscar Wiklander

iTRANSLATE-BREAST. Intergrate real-life platform for biomarker discovery and outcome-based translational research for breast cancer patients

Andri Papakonstantinou

SentiNot 2.0. Use of superparamagnetic iron oxide (SPIO) tracer to avoid unnecessary sentinel node biopsies (SNB)

Helena Sackey

MK2870-032. Randomized Phase 3 Open-label Active Controlled Study of Sacituzumab Tirumotecan (sac-TMT / MK-2870) in Early Triple Negative Breast Cancer (eTNBC

Theodoros Foukakis

MK2870-012 TroFuse-012. A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surger

Theo Foukakis

SentiNeo 2.0. Axillary lymph node localisation before neoadjuvant chemotherapy using MagTrace, (superparamagnetic iron oxide nanoparticles, SPIO) and Magseed, in clinically node negative and node positive patients: SENTINEO 2.0

Helena Sackey

Kogni-Thyr-studien . Prospective longitudinal evaluation of objective cognitive function and quality of life in patients undergoing surgery for malignant and benign thyroid nodules Cognition and QoL in patients undergoing thyroid surgery

Karin Lind

START-NET. Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine TumorsAn open-label, multi-center, randomized phase III controlled trial comparing safety and efficacy of trial comparing safety and efficacy of personalized vs non-personalized personalized vs non-personalized radionuclide therapy with 177Lu-DOTATOC

David Goldstein

ADIUVO-2. Adjuvant mitotane vs. mitotane with cisplatin/etoposide after primary surgical resection of localised adrenocortical carcinoma with high risk of recurrence (ADIUVO-2 Trial): A pragmatic, randomised, low-intervention phase III, clinical trial with an observational arm.

David Goldstein

PERELI. A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated LIposarcoma

Andri Papakonstantinou

PREP. PREvention and Prediction of breast-and ovarian cancer - PREP

Angelique Flöter Rådestad

TUBA-WISP II. Tubectomy with delayed oophorectomy as alternative for risk reducing salpingo-oophorectomy in BRCA-women to assess the safety of prevention

Angelique Flöter Rådestad